Full-Time
Handheld ultrasound device for point-of-care imaging
$180k - $200k/yr
No H1B Sponsorship
San Francisco, CA, USA + 1 more
More locations: Burlington, MA, USA
Hybrid
Hybrid role; two or more days per week in the office; based out of Burlington, MA or San Francisco Bay Area.
Master's, PhD
See people who can refer or advise you
Butterfly Network makes medical imaging tools, focusing on point-of-care ultrasound (POCUS). Its main product is the Butterfly iQ, a handheld ultrasound device that uses a single probe to scan the whole body. The iQ connects to a software platform, storing images, supporting telehealth, and providing advanced imaging tools. The device is sold to doctors, nurses, and medical technicians in hospitals, clinics, and rural settings, with revenue from device sales, software subscriptions, and educational resources. What sets Butterfly Network apart is its single-probe, portable design that aims to simplify ultrasound workflows and make high-quality imaging more affordable and accessible, especially in underserved areas. The company’s goal is to improve diagnostic access and patient outcomes worldwide by delivering cost-effective, easy-to-use ultrasound technology that integrates hardware and software in one connected system.
Company Size
201-500
Company Stage
IPO
Headquarters
Burlington, Massachusetts
Founded
2011
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health, dental & vision insurance
Equity
401k
PTO
Flexible hybrid work
Parental leave
Home office stipend
Rewards & recognition program
LinkedIn Learning
Joseph Devivo, president and CEO of Butterfly Network, sold 68,346 shares of Class A common stock on 10 August 2026, according to a SEC Form 4 filing. The transaction, valued at approximately $684,143, was executed through a Rule 10b5-1 trading plan adopted in December 2025. Following the sale, Devivo retains direct ownership of approximately 7.6 million shares, representing a market value of roughly $74 million. Butterfly Network shares closed at $9.37 on 11 August 2026, having achieved a 629% return over the preceding 12 months. The Burlington-based medical device company, which manufactures portable ultrasound imaging devices including the Butterfly iQ, reported trailing-twelve-month revenue of $112 million and a net loss of $75 million. The company maintains a market capitalisation of $2.3 billion.
Butterfly Network raised its full-year 2026 revenue guidance to $119 million–$123 million, driven by growth in Point-of-Care Ultrasound, Home and Community Care, and Embedded partnerships. The company reported record gross margins of 71%, attributed to high-margin contributions from its Embedded segment. The Embedded business saw revenue increase 439%, primarily from the Midjourney partnership. Butterfly's enterprise software pipeline, Compass AI, has grown fivefold since last year. The company now serves 80% of US medical schools. International revenue fell 14% due to timing of large deals shifting to Q3. The company expects its first Home and Community Care commercial implementation on 1 October, with Q4 revenue anticipated. Butterfly plans to launch a next-generation probe in Q1 2027 and enter the ultrasound cart market in late 2027 with iQ Station.
Jonathan Rothberg, founder and independent director of Butterfly Network, sold approximately 3.1 million Class B shares at $6.64 each, totalling $20.7 million, according to an SEC filing. The sale was conducted under a Rule 10b5-1 trading plan adopted in March 2026 for estate planning purposes. Following the transaction, Rothberg directly holds roughly 106,000 shares and indirectly controls about 19.6 million shares through various entities including family trusts. The sale occurred as Butterfly Network shares returned 263% over the preceding 12 months. Butterfly Network develops portable ultrasound imaging devices that connect to smartphones and tablets. The company has a market capitalisation of $1.8 billion, with trailing twelve-month revenue of $102.9 million and a net loss of $75.8 million.
Butterfly Network CEO Joseph Devivo sold nearly 212,000 shares of Class A Common Stock on 20 July 2026, valued at $1.4 million, according to an SEC Form 4 filing. The transaction was automatically executed to cover tax withholding obligations from vesting restricted stock units. Following the sale, Devivo retains 7,672,046 shares worth $51.33 million at the 20 July market close. The Burlington-based medical device company's shares have surged 260% over the past year. Butterfly Network designs portable ultrasound imaging devices, including the Butterfly iQ series, which connect to smartphones and tablets. The firm reported trailing-twelve-month revenue of $102.9 million and holds a market capitalisation of $1.8 billion, despite posting a net loss of $75.8 million.
Butterfly Network has launched its Butterfly iQ+ and iQ3 handheld ultrasound devices in Brazil through authorised distribution partners, marking a significant expansion into Latin America's largest medical device market. The move follows the company meeting Brazil's regulatory and certification requirements. Despite the announcement, BFLY shares fell 3.2% yesterday, though the stock has climbed 102.1% year to date, outperforming both the industry and S&P 500. The company currently holds a $2.02 billion market capitalisation. Brazil's healthcare system, particularly in remote areas, presents opportunities for Butterfly Network's portable ultrasound technology. The devices use proprietary Ultrasound-on-Chip technology and work with iOS and Android devices, enabling whole-body imaging with a single handheld unit. The semiconductor-based design offers a more accessible alternative to conventional ultrasound systems.